The post hoc findings from a phase 2 clinical trial (NCT01683409) showed that patients with DKD who were treated with baricitinib (JAK1 and JAK2 inhibitor) achieved noticeable improvements in lowering proteinuria and decreasing levels of inflammatory cytokines in urine and blood (Tuttle et al., 2018). The gene discussed is JAK2; the disease is diabetic kidney disease.